Stryker Return on Tangible Equity 2010-2025 | SYK
Current and historical return on tangible equity values for Stryker (SYK) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
| Stryker Return On Tangible Equity Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Tangible Equity | Return on Tangible Equity |
| 2025-03-31 | $2.86B | $-4.29B | -224.10% |
| 2024-12-31 | $2.99B | $0.38B | -798.13% |
| 2024-09-30 | $3.59B | $-1.19B | -459.23% |
| 2024-06-30 | $3.45B | $-0.01B | -353.28% |
| 2024-03-31 | $3.36B | $-0.69B | -202.99% |
| 2023-12-31 | $3.17B | $-1.24B | -146.05% |
| 2023-09-30 | $2.59B | $-1.96B | -97.79% |
| 2023-06-30 | $2.71B | $-2.73B | -88.87% |
| 2023-03-31 | $2.63B | $-2.73B | -74.26% |
| 2022-12-31 | $2.36B | $-3.15B | -55.38% |
| 2022-09-30 | $2.46B | $-3.58B | -58.63% |
| 2022-06-30 | $2.08B | $-4.69B | -49.06% |
| 2022-03-31 | $2.02B | $-5.61B | -48.82% |
| 2021-12-31 | $1.99B | $-2.88B | -51.21% |
| 2021-09-30 | $1.90B | $-3.77B | -42.36% |
| 2021-06-30 | $2.08B | $-4.24B | -58.56% |
| 2021-03-31 | $1.41B | $-4.68B | -54.58% |
| 2020-12-31 | $1.60B | $-5.25B | -113.08% |
| 2020-09-30 | $1.76B | $-0.06B | -783.05% |
| 2020-06-30 | $1.60B | $-0.33B | -499.14% |
| 2020-03-31 | $2.16B | $-0.02B | -442.99% |
| 2019-12-31 | $2.08B | $-0.49B | -260.86% |
| 2019-09-30 | $3.43B | $-0.45B | -370.28% |
| 2019-06-30 | $3.55B | $-1.00B | -316.05% |
| 2019-03-31 | $3.52B | $-1.26B | -269.21% |
| 2018-12-31 | $3.55B | $-1.00B | -230.53% |
| 2018-09-30 | $1.24B | $-1.24B | -84.74% |
| 2018-06-30 | $1.08B | $-1.74B | -92.54% |
| 2018-03-31 | $1.02B | $-2.19B | -148.60% |
| 2017-12-31 | $1.02B | $-0.67B | -592.16% |
| 2017-09-30 | $1.78B | $-0.07B | -2105.33% |
| 2017-06-30 | $1.70B | $0.18B | -667.98% |
| 2017-03-31 | $1.69B | $-0.14B | -306.81% |
| 2016-12-31 | $1.65B | $-0.31B | 827.64% |
| 2016-09-30 | $1.66B | $-0.75B | 179.79% |
| 2016-06-30 | $1.61B | $-1.00B | 92.98% |
| 2016-03-31 | $1.62B | $2.86B | 62.42% |
| 2015-12-31 | $1.44B | $2.58B | 58.97% |
| 2015-09-30 | $1.18B | $2.46B | 49.19% |
| 2015-06-30 | $0.93B | $2.46B | 39.84% |
| 2015-03-31 | $0.67B | $2.26B | 27.52% |
| 2014-12-31 | $0.52B | $2.39B | 19.73% |
| 2014-09-30 | $0.64B | $2.26B | 22.76% |
| 2014-06-30 | $0.69B | $2.81B | 20.20% |
| 2014-03-31 | $0.77B | $2.98B | 20.22% |
| 2013-12-31 | $1.01B | $3.21B | 24.19% |
| 2013-09-30 | $0.89B | $4.60B | 19.29% |
| 2013-06-30 | $1.14B | $4.49B | 24.23% |
| 2013-03-31 | $1.25B | $4.34B | 26.48% |
| 2012-12-31 | $1.30B | $5.03B | 27.21% |
| 2012-09-30 | $1.43B | $4.96B | 31.38% |
| 2012-06-30 | $1.40B | $4.58B | 32.40% |
| 2012-03-31 | $1.39B | $4.52B | 32.47% |
| 2011-12-31 | $1.35B | $4.17B | 31.89% |
| 2011-09-30 | $1.24B | $4.06B | 27.38% |
| 2011-06-30 | $1.25B | $4.35B | 25.31% |
| 2011-03-31 | $1.26B | $4.29B | 24.49% |
| 2010-12-31 | $1.27B | $5.40B | 23.89% |
| 2010-09-30 | $1.28B | $5.70B | 24.55% |
| 2010-06-30 | $1.18B | $5.16B | 22.72% |
| 2010-03-31 | $1.15B | $5.05B | 22.23% |
| 2009-12-31 | $1.11B | $5.00B | 21.79% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $153.031B | $22.595B |
| Stryker Corporation is a medical device company operating in the global orthopedic market. The company has three business segments: Orthopaedics, MedSurg and Neurotechnology & Spine. Orthopaedic?products include implants used in hip and knee joint replacements and trauma and extremities surgeries. MedSurg?products consists of surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment and reprocessed and remanufactured medical devices. Neurotechnology & Spine division includes both neurosurgical and neurovascular devices. These includes products used for minimally invasive endovascular techniques; traditional brain and open skull base surgical procedures; orthobiologic and biosurgery products and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. Spinal implant product offering includes cervical, thoracolumbar and interbody systems used in spinal injury, deformity and degenerative therapies. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $218.924B | 25.68 |
| Boston Scientific (BSX) | United States | $159.425B | 38.08 |
| EssilorLuxottica (ESLOY) | France | $136.054B | 0.00 |
| Medtronic (MDT) | Ireland | $118.007B | 16.73 |
| Lonza Group Ag (LZAGY) | Switzerland | $50.909B | 0.00 |
| Haleon (HLN) | United Kingdom | $43.800B | 25.00 |
| ResMed (RMD) | United States | $40.084B | 30.11 |
| GE HealthCare Technologies (GEHC) | United States | $35.372B | 16.79 |
| Agilent Technologies (A) | United States | $33.937B | 22.12 |
| Terumo (TRUMY) | Japan | $25.318B | 32.88 |
| Koninklijke Philips (PHG) | Netherlands | $24.891B | 17.47 |
| Insulet (PODD) | United States | $20.174B | 79.19 |
| Zimmer Biomet Holdings (ZBH) | United States | $19.257B | 12.37 |
| Baxter (BAX) | United States | $14.656B | 10.94 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $13.945B | 0.00 |
| Sunny Optical Technology (SNPTF) | China | $10.417B | 0.00 |
| Demant (WILYY) | Denmark | $8.633B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $6.996B | 24.34 |
| Lantheus Holdings (LNTH) | United States | $5.072B | 12.79 |
| Perrigo (PRGO) | Ireland | $3.866B | 9.80 |
| Prestige Consumer Healthcare (PBH) | United States | $3.792B | 16.94 |
| Haemonetics (HAE) | United States | $3.582B | 16.32 |
| Envista Holdings (NVST) | United States | $3.517B | 29.23 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.459B | 0.00 |
| ICU Medical (ICUI) | United States | $3.175B | 23.41 |
| LeMaitre Vascular (LMAT) | United States | $1.856B | 41.49 |
| QuidelOrtho (QDEL) | United States | $1.799B | 12.37 |
| AtriCure (ATRC) | United States | $1.526B | 0.00 |
| Acuren (TIC) | United States | $1.435B | 0.00 |
| AdaptHealth (AHCO) | United States | $1.301B | 13.20 |
| Green Thumb Industries (GTBIF) | United States | $1.217B | 27.38 |
| Phibro Animal Health (PAHC) | United States | $1.208B | 15.44 |
| Neogen (NEOG) | United States | $1.098B | 14.06 |
| BioLife Solutions (BLFS) | United States | $1.074B | 0.00 |
| InMode (INMD) | Israel | $0.944B | 9.51 |
| Kestra Medical Technologies (KMTS) | United States | $0.859B | 0.00 |
| Curaleaf Holdings (CURLF) | Canada | $0.838B | 0.00 |
| Tilray Brands (TLRY) | Canada | $0.741B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.667B | 0.00 |
| Owens & Minor (OMI) | United States | $0.637B | 5.28 |
| Valneva SE (VALN) | France | $0.622B | 0.00 |
| Evolus (EOLS) | United States | $0.618B | 0.00 |
| CeriBell (CBLL) | United States | $0.569B | 0.00 |
| ZimVie (ZIMV) | United States | $0.523B | 23.77 |
| Surmodics (SRDX) | United States | $0.464B | 0.00 |
| SNDL (SNDL) | Canada | $0.420B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.317B | 11.65 |
| Sanuwave Health (SNWV) | United States | $0.315B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.314B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.312B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.298B | 0.00 |
| Quanterix (QTRX) | United States | $0.284B | 0.00 |
| Cerus (CERS) | United States | $0.277B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.274B | 81.33 |
| Viemed Healthcare (VMD) | United States | $0.255B | 21.53 |
| OraSure Technologies (OSUR) | United States | $0.247B | 0.00 |
| Sanara MedTech (SMTI) | United States | $0.243B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.240B | 0.00 |
| Biote (BTMD) | United States | $0.232B | 6.52 |
| Brainsway (BWAY) | Israel | $0.225B | 59.45 |
| Omeros (OMER) | United States | $0.224B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.217B | 0.00 |
| Organigram Global (OGI) | Canada | $0.208B | 0.00 |
| High Tide (HITI) | Canada | $0.196B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.189B | 15.39 |
| TriSalus Life Sciences (TLSI) | United States | $0.178B | 0.00 |
| Exagen (XGN) | United States | $0.156B | 0.00 |
| Vireo Growth (VREOF) | United States | $0.151B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.127B | 15.65 |
| TerrAscend (TSNDF) | Canada | $0.116B | 0.00 |
| MacroGenics (MGNX) | United States | $0.114B | 0.00 |
| Jin Medical (ZJYL) | China | $0.110B | 0.00 |
| Safety Shot (SHOT) | United States | $0.105B | 0.00 |
| Fonar (FONR) | United States | $0.101B | 12.98 |
| Quipt Home Medical (QIPT) | United States | $0.097B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.094B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.087B | 0.00 |
| Apyx Medical (APYX) | United States | $0.086B | 0.00 |
| Veru (VERU) | United States | $0.086B | 0.00 |
| Zynex (ZYXI) | United States | $0.076B | 0.00 |
| Agape ATP (ATPC) | $0.074B | 0.00 | |
| InterCure (INCR) | Israel | $0.070B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.064B | 0.00 |
| ImmuCell (ICCC) | United States | $0.063B | 0.00 |
| United-Guardian (UG) | United States | $0.044B | 15.21 |
| Modular Medical (MODD) | United States | $0.039B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.038B | 0.00 |
| Nephros (NEPH) | United States | $0.037B | 50.43 |
| Allurion Technologies (ALUR) | United States | $0.024B | 0.00 |
| INLIF (INLF) | $0.015B | 0.00 | |
| Flora Growth (FLGC) | United States | $0.014B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.013B | 0.00 |
| Senestech (SNES) | United States | $0.013B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.013B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.012B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.010B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.007B | 0.00 |
| Sharps Technology (STSS) | United States | $0.006B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.004B | 0.00 |
| Akanda (AKAN) | Canada | $0.002B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |